CA2064574A1 - Produit et traitement pour soigner l'intoxication a la cocaine et empecher la recidive pendant et apres le traitement, grace a un antagoniste de la cocaine, de l'amphetamine et dela phencyclidine - Google Patents
Produit et traitement pour soigner l'intoxication a la cocaine et empecher la recidive pendant et apres le traitement, grace a un antagoniste de la cocaine, de l'amphetamine et dela phencyclidineInfo
- Publication number
- CA2064574A1 CA2064574A1 CA002064574A CA2064574A CA2064574A1 CA 2064574 A1 CA2064574 A1 CA 2064574A1 CA 002064574 A CA002064574 A CA 002064574A CA 2064574 A CA2064574 A CA 2064574A CA 2064574 A1 CA2064574 A1 CA 2064574A1
- Authority
- CA
- Canada
- Prior art keywords
- halo
- hydrido
- cocaine
- carbon atoms
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 title claims abstract description 94
- 229960003920 cocaine Drugs 0.000 title claims abstract description 47
- 239000005557 antagonist Substances 0.000 title abstract description 13
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 title description 64
- 229960003638 dopamine Drugs 0.000 title description 32
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 title description 10
- 229940025084 amphetamine Drugs 0.000 title description 10
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 title description 10
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 title description 10
- 230000036964 tight binding Effects 0.000 title description 6
- 229940076279 serotonin Drugs 0.000 title description 5
- 229950010883 phencyclidine Drugs 0.000 title description 4
- 239000000221 dopamine uptake inhibitor Substances 0.000 title 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 title 1
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 title 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 18
- 230000001154 acute effect Effects 0.000 claims abstract description 9
- 235000019788 craving Nutrition 0.000 claims abstract description 9
- 208000022497 Cocaine-Related disease Diseases 0.000 claims abstract description 6
- 241000124008 Mammalia Species 0.000 claims abstract description 6
- 201000006145 cocaine dependence Diseases 0.000 claims abstract 4
- 206010013663 drug dependence Diseases 0.000 claims abstract 4
- 125000000217 alkyl group Chemical group 0.000 claims description 33
- -1 cyano, carboxyl Chemical group 0.000 claims description 29
- 150000001875 compounds Chemical class 0.000 claims description 28
- 125000004432 carbon atom Chemical group C* 0.000 claims description 24
- 125000001145 hydrido group Chemical group *[H] 0.000 claims description 23
- 125000003545 alkoxy group Chemical group 0.000 claims description 18
- NAUWTFJOPJWYOT-UHFFFAOYSA-N vanoxerine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)OCCN1CCN(CCCC=2C=CC=CC=2)CC1 NAUWTFJOPJWYOT-UHFFFAOYSA-N 0.000 claims description 17
- 125000003342 alkenyl group Chemical group 0.000 claims description 15
- 125000001188 haloalkyl group Chemical group 0.000 claims description 13
- 125000003282 alkyl amino group Chemical group 0.000 claims description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 125000004414 alkyl thio group Chemical group 0.000 claims description 8
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims description 8
- 125000000304 alkynyl group Chemical group 0.000 claims description 7
- 239000003085 diluting agent Substances 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 206010012335 Dependence Diseases 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 21
- 229940125904 compound 1 Drugs 0.000 claims 3
- 125000004663 dialkyl amino group Chemical group 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 22
- 229940079593 drug Drugs 0.000 abstract description 21
- 238000011282 treatment Methods 0.000 abstract description 13
- 230000037396 body weight Effects 0.000 abstract description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract description 3
- 208000017781 Cocaine intoxication Diseases 0.000 abstract description 2
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 18
- 239000003795 chemical substances by application Substances 0.000 description 10
- 238000009472 formulation Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 7
- 241000282412 Homo Species 0.000 description 6
- 239000000935 antidepressant agent Substances 0.000 description 6
- 125000005843 halogen group Chemical group 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 4
- 206010013654 Drug abuse Diseases 0.000 description 4
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 229960000299 mazindol Drugs 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 229960002748 norepinephrine Drugs 0.000 description 4
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 201000009032 substance abuse Diseases 0.000 description 4
- RAQPOZGWANIDQT-UHFFFAOYSA-N 1-[2-(benzhydryloxy)ethyl]-4-(3-phenylpropyl)piperazine Chemical compound C=1C=CC=CC=1CCCN(CC1)CCN1CCOC(C=1C=CC=CC=1)C1=CC=CC=C1 RAQPOZGWANIDQT-UHFFFAOYSA-N 0.000 description 3
- 206010015535 Euphoric mood Diseases 0.000 description 3
- 229940005513 antidepressants Drugs 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000003291 dopaminomimetic effect Effects 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000002427 irreversible effect Effects 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 230000000966 norepinephrine reuptake Effects 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000012064 sodium phosphate buffer Substances 0.000 description 3
- 241001539473 Euphoria Species 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- GIJXKZJWITVLHI-PMOLBWCYSA-N benzatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(C=1C=CC=CC=1)C1=CC=CC=C1 GIJXKZJWITVLHI-PMOLBWCYSA-N 0.000 description 2
- 229960001081 benzatropine Drugs 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 201000001272 cocaine abuse Diseases 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000008517 inhibition of serotonin uptake Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 238000001690 micro-dialysis Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000010082 neurochemical mechanism Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- XXPANQJNYNUNES-UHFFFAOYSA-N nomifensine Chemical compound C12=CC=CC(N)=C2CN(C)CC1C1=CC=CC=C1 XXPANQJNYNUNES-UHFFFAOYSA-N 0.000 description 2
- 229960001073 nomifensine Drugs 0.000 description 2
- 125000006684 polyhaloalkyl group Polymers 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- MBFDHHKTIBKZNR-UHFFFAOYSA-N 1-(2-benzhydryloxyethyl)piperazine Chemical class C=1C=CC=CC=1C(C=1C=CC=CC=1)OCCN1CCNCC1 MBFDHHKTIBKZNR-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- VYFYYTLLBUKUHU-WTJCDBBSSA-N 4-(2-amino-1,1-ditritioethyl)benzene-1,2-diol Chemical compound NCC([3H])([3H])C1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-WTJCDBBSSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000029197 Amphetamine-Related disease Diseases 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 201000002472 amphetamine abuse Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000001102 biogenic amine re-uptake Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- WKCDAAPJCSPOHY-UHFFFAOYSA-N chloroethane;hydrate Chemical compound O.CCCl WKCDAAPJCSPOHY-UHFFFAOYSA-N 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 125000004982 dihaloalkyl group Chemical group 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229940052760 dopamine agonists Drugs 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 230000002743 euphoric effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 208000031424 hyperprolactinemia Diseases 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000001535 kindling effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000006682 monohaloalkyl group Chemical group 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 125000005004 perfluoroethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 208000007100 phencyclidine abuse Diseases 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000003578 releasing effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 230000000697 serotonin reuptake Effects 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38886689A | 1989-08-03 | 1989-08-03 | |
| US388,866 | 1989-08-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2064574A1 true CA2064574A1 (fr) | 1991-02-04 |
Family
ID=23535858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002064574A Abandoned CA2064574A1 (fr) | 1989-08-03 | 1990-08-03 | Produit et traitement pour soigner l'intoxication a la cocaine et empecher la recidive pendant et apres le traitement, grace a un antagoniste de la cocaine, de l'amphetamine et dela phencyclidine |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0485512A4 (fr) |
| JP (1) | JPH0672098B2 (fr) |
| AU (1) | AU629688B2 (fr) |
| CA (1) | CA2064574A1 (fr) |
| WO (1) | WO1991001732A1 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001506978A (ja) | 1996-10-31 | 2001-05-29 | アメリカ合衆国 | 置換１―［２［ビス（アリール）メトキシ］エチル］―ピペラジンおよび―ホモピペラジンのヒドロキシル化類似物の持続性放出誘導体およびそのドパミン再アップテイクの非競合的拮抗物質としての使用 |
| US6743797B2 (en) | 2002-02-22 | 2004-06-01 | Chantest, Inc. | Methods for treating cardiac arrhythmia |
| US7211407B2 (en) | 2003-07-15 | 2007-05-01 | Chan Test, Inc. | High throughput assay systems and methods for identifying agents that alter surface expression of integral membrane proteins |
| US20050208595A1 (en) | 2004-03-19 | 2005-09-22 | Brown Arthur M | High throughput assay systems and methods for identifying agents that alter expression of cellular proteins |
| US11096901B2 (en) | 2009-03-06 | 2021-08-24 | Metaqor Llc | Dynamic bio-nanoparticle platforms |
| WO2014059346A1 (fr) * | 2012-10-11 | 2014-04-17 | Brown Arthur M | Procédés de traitement d'états impliquant la dopamine par l'administration de composés de pipérazine |
| US20160304477A1 (en) * | 2013-04-26 | 2016-10-20 | Laguna Pharmaceuticals, Inc. | Novel metabolites of vanoxerine compounds, pharmaceutical compositions containing the same and methods of terminating acute episodes of cardiac arrhythmia, restoring normal sinus rhythm, preventing recurrence of cardiac arrhythmia and maintaining normal sinus rhythm in mammals |
| US20210353771A1 (en) * | 2020-04-30 | 2021-11-18 | Metaqor Llc | Compositions and Methods for Treating Dopamine Disorders |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR861128B (en) * | 1985-05-06 | 1986-08-26 | Sandoz Ag | New use of dopamine agonists |
| US4935429A (en) * | 1985-10-25 | 1990-06-19 | Dackis Charles A | Method of treating psychostimulant addiction |
| HU196194B (en) * | 1986-04-28 | 1988-10-28 | Richter Gedeon Vegyeszet | Process for producing new 1-4 disubstituted piperazines and pharmaceuticals comprising the compounds |
-
1990
- 1990-08-03 AU AU62778/90A patent/AU629688B2/en not_active Ceased
- 1990-08-03 JP JP2511873A patent/JPH0672098B2/ja not_active Expired - Lifetime
- 1990-08-03 EP EP19900913049 patent/EP0485512A4/en not_active Withdrawn
- 1990-08-03 CA CA002064574A patent/CA2064574A1/fr not_active Abandoned
- 1990-08-03 WO PCT/US1990/004360 patent/WO1991001732A1/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU6277890A (en) | 1991-03-11 |
| AU629688B2 (en) | 1992-10-08 |
| EP0485512A4 (en) | 1992-08-26 |
| JPH04504859A (ja) | 1992-08-27 |
| EP0485512A1 (fr) | 1992-05-20 |
| JPH0672098B2 (ja) | 1994-09-14 |
| WO1991001732A1 (fr) | 1991-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2095062C1 (ru) | Блокатор синдрома отмены, являющегося результатом привыкания к чрезмерному потреблению лекарств или веществ, вызывающих привыкание, фармакологическая композиция на его основе и способ облегчения или предотвращения синдрома отмены | |
| IE83379B1 (en) | New use of diphenylbutylpiperazinecarboxamides in the treatment of substance abuse | |
| US5059600A (en) | Treating habit disorders | |
| AU629688B2 (en) | Slowly dissociating (tight binding) dopamine, serotonin or norepinephrine reuptake inhibitors as cocaine, amphetamine and phencyclidine antagonists | |
| JP3245642B2 (ja) | 物質濫用疾患治療剤 | |
| YU6196A (sh) | Transdermalna flasterska formulacija | |
| US5340826A (en) | Pharmaceutical agents for treatment of urinary incontinence | |
| EP0319962A2 (fr) | Dérivés de la pipéridinyl méthanol pour le traitement de l'anxiété | |
| JP2005507411A (ja) | 下肢静止不能症候群の治療における、ニコチン性アセチルコリン受容体アゴニスト。 | |
| US6841557B2 (en) | Compounds for the treatment of addictive disorders | |
| NL8002041A (nl) | Werkwijze voor het bereiden van een analgetisch en myotonolytisch geneesmiddel. | |
| US6221858B1 (en) | Pyridyl-and pyrimidyl-piperazines in the treatment of substance abuse disorders | |
| US20030134844A1 (en) | Nicontinic acetylcholine receptor antagonists in the treatment of restless legs syndrome | |
| JP4357958B2 (ja) | オピオイド依存症の治療のためのピリジン−２−イル−メチルアミン誘導体 | |
| TW200530218A (en) | Drug for inhibiting vascular intimal hyperplasia | |
| EP0659409A2 (fr) | Antagonistes de la substance P pour l'inhibition de l'angiogénése | |
| CA2261676A1 (fr) | Procede de traitement d'une agressivite excessive | |
| JPH07502517A (ja) | 精神病の治療のためのアリールインドールの使用 | |
| JPH10101564A (ja) | 鼻炎予防及び／又は治療剤 | |
| JPH10508837A (ja) | 眼の疾患を治療するためのｎｋ−１レセプターアンタゴニスト | |
| EP1685838A1 (fr) | méthodes de traitement de la toxicomanie | |
| ZA200300220B (en) | Compounds for the treatment of addictive disorders. | |
| HK1008931A (en) | Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline ) for treating excessive aggression |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |